These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 20407889)

  • 1. Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.
    Polyzos SA; Kountouras J; Anastasilakis AD; Litsas I; Kita M; Arsos G; Moralidis E; Terpos E
    Osteoporos Int; 2011 Jan; 22(1):363-7. PubMed ID: 20407889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid-induced hepatotoxicity relieved after subsequent infusions in a Chinese woman with glucocorticoid-induced osteoporosis.
    Jiang Y; Fu Y; Xing XP; Li M; Wang O; Xia WB; Meng XW
    Eur J Med Res; 2015 Aug; 20(1):68. PubMed ID: 26297149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent effect of zoledronic acid in Paget's disease.
    Tziomalos K; Florentin M; Krikis N; Perifanis V; Karagiannis A; Harsoulis F
    Clin Exp Rheumatol; 2007; 25(3):464-6. PubMed ID: 17631747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profound hypocalcemia following effective response to zoledronic acid treatment in a patient with juvenile Paget's disease.
    Polyzos SA; Anastasilakis AD; Litsas I; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Papatheodorou A; Terpos E
    J Bone Miner Metab; 2010 Nov; 28(6):706-12. PubMed ID: 20533067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
    Abelson A
    Curr Med Res Opin; 2008 Mar; 24(3):695-705. PubMed ID: 18226324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
    Hosking D; Lyles K; Brown JP; Fraser WD; Miller P; Curiel MD; Devogelaer JP; Hooper M; Su G; Zelenakas K; Pak J; Fashola T; Saidi Y; Eriksen EF; Reid IR
    J Bone Miner Res; 2007 Jan; 22(1):142-8. PubMed ID: 17032148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years.
    Reid IR; Lyles K; Su G; Brown JP; Walsh JP; del Pino-Montes J; Miller PD; Fraser WD; Cafoncelli S; Bucci-Rechtweg C; Hosking DJ
    J Bone Miner Res; 2011 Sep; 26(9):2261-70. PubMed ID: 21638319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of zoledronic acid for Paget's disease of bone.
    Maricic M
    Curr Osteoporos Rep; 2006 Mar; 4(1):40-4. PubMed ID: 16527007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Treatment of Paget's disease of bone with zoledronic acid].
    Body JJ; Sternon J
    Rev Med Brux; 2005; 26(6):513-7. PubMed ID: 16454155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute myopericarditis following intravenous zoledronic acid for the treatment of Paget's disease.
    Watts MR; Ellims AH; Eccleston DS
    Med J Aust; 2014 Feb; 200(3):150. PubMed ID: 24528425
    [No Abstract]   [Full Text] [Related]  

  • 11. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone.
    Keating GM; Scott LJ
    Drugs; 2007; 67(5):793-804. PubMed ID: 17385948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget's disease of bone.
    Avramidis A; Polyzos SA; Moralidis E; Arsos G; Efstathiadou Z; Karakatsanis K; Grollios G; Kita M
    J Bone Miner Metab; 2008; 26(6):635-41. PubMed ID: 18979164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intravenous bisphosphonates for bone Paget's disease: higher risk of adverse events].
    Grados D; Martínez-Morillo M; Holgado S; Erra A
    Med Clin (Barc); 2014 May; 142(10):469-70. PubMed ID: 24120108
    [No Abstract]   [Full Text] [Related]  

  • 14. [Zoledronic acid efficacy in Paget's disease of bone: a three-year experience].
    Conesa Mateos A; Rotés Sala D; Almirall Bernabé M; Carbonell Abelló J
    Med Clin (Barc); 2006 Oct; 127(16):635-6. PubMed ID: 17145033
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
    Reid IR; Miller P; Lyles K; Fraser W; Brown JP; Saidi Y; Mesenbrink P; Su G; Pak J; Zelenakas K; Luchi M; Richardson P; Hosking D
    N Engl J Med; 2005 Sep; 353(9):898-908. PubMed ID: 16135834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged anti-resorptive activity of zoledronic acid: evidence from postmenopausal osteopenic women and patients with Paget's disease of bone.
    Polyzos SA
    Clin Rheumatol; 2011 Jan; 30(1):149-50. PubMed ID: 21053036
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug-induced hepatotoxicity linked to zoledronic acid in the treatment of an elderly man with primary osteoporosis.
    Chen W; Zhu M
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):721-724. PubMed ID: 34423770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Symptomatic intracranial hypertension and prolonged hypocalcemia following treatment of Paget's disease of the skull with zoledronic acid.
    Ferraz-de-Souza B; Martin RM; Correa PH
    J Bone Miner Metab; 2013 May; 31(3):360-5. PubMed ID: 23076294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-energy X-ray absorptiometry and quantitative ultrasound in patients with Paget's disease of bone before and after treatment with zoledronic acid: association with serum bone markers and Dickkopf-1.
    Polyzos SA; Anastasilakis AD; Litsas I; Sapranidis M; Efstathiadou Z; Kita M; Arsos G; Moralidis E; Zafeiriadou E; Papatheodorou A; Terpos E
    J Clin Densitom; 2010; 13(2):190-6. PubMed ID: 20347367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zoledronic acid for treatment of Paget's disease of bone.
    Devogelaer JP; Manicourt DH
    Expert Opin Pharmacother; 2007 Nov; 8(16):2863-9. PubMed ID: 17956205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.